N
Noémie Tavernier
Researcher at university of lille
Publications - 6
Citations - 231
Noémie Tavernier is an academic researcher from university of lille. The author has contributed to research in topics: Prospective cohort study & Vedolizumab. The author has an hindex of 4, co-authored 6 publications receiving 194 citations.
Papers
More filters
Journal ArticleDOI
Validation of the inflammatory bowel disease disability index in a population-based cohort
Corinne Gower-Rousseau,Hélène Sarter,Guillaume Savoye,Noémie Tavernier,Mathurin Fumery,William J. Sandborn,Brian G. Feagan,Alain Duhamel,Nathalie Guillon-Dellac,Jean-Frederic Colombel,Laurent Peyrin-Biroulet +10 more
TL;DR: The Inflammatory Bowel Disease Disability Index (IBD-DI) has been validated for use in clinical trials and epidemiological studies and showed high internal consistency, interobserver reliability and construct validity, and a moderate intraob server reliability.
Journal ArticleDOI
Systematic review: fertility in non-surgically treated inflammatory bowel disease
Noémie Tavernier,Mathurin Fumery,Laurent Peyrin-Biroulet,Jean-Frederic Colombel,Corinne Gower-Rousseau +4 more
TL;DR: Inflammatory bowel diseases (IBD) typically affect young patients during the reproductive years, and reproductive issues are of key concern to them.
Journal ArticleDOI
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
Pauline Wils,Philippe Seksik,Carmen Stefanescu,Stéphane Nancey,Matthieu Allez,Guillaume Pineton de Chambrun,Romain Altwegg,Cyrielle Gilletta,Lucine Vuitton,Stephanie Viennot,Mélanie Serrero,Mathurin Fumery,Guillaume Savoye,Michael Collins,Felix Goutorbe,Hedia Brixi,Guillaume Bouguen,Noémie Tavernier,Medina Boualit,Aurelien Amiot,Vered Abitbol,David Laharie,Benjamin Pariente +22 more
TL;DR: In this paper, the authors performed a retrospective cohort study among women with inflammatory bowel diseases (IBD) who received ustekinumab or vedolizumab during pregnancy or within the 2 months before conception and compared outcomes to women exposed to anti-TNF treatment during pregnancy.
Journal ArticleDOI
Post-operative recurrence of Crohn's disease after definitive stoma: an underestimated risk.
Dine Koriche,Corinne Gower-Rousseau,Charbel Chater,Alain Duhamel,Julia Salleron,Noémie Tavernier,Jean-Frederic Colombel,Jean-Frederic Colombel,Benjamin Pariente,Antoine Cortot,P. Zerbib +10 more
TL;DR: After DS for Crohn’s disease, the risk of clinical recurrence was high and synonymous with surgical recurrence, especially for patients with APL and colostomy.
Journal ArticleDOI
P447 No severe neonatal and maternal complications in inflammatory bowel diseases patients treated with ustekinumab or vedolizumab during pregnancy
Pauline Wils,P. Seksik,Carmen Stefanescu,Stéphane Nancey,Mathieu Allez,D. Laharie,G Pineton de Chambrun,Romain Altwegg,Cyrielle Gilletta,Lucine Vuitton,Stephanie Viennot,Mélanie Serrero,Mathurin Fumery,G. Savoye,Michael T. Collins,Felix Goutorbe,Hedia Brixi,Guillaume Bouguen,Noémie Tavernier,Medina Boualit,Aurelien Amiot,Vered Abitbol,Benjamin Pariente +22 more
TL;DR: No serious neonatal or maternal complications were observed in female IBD patients who received at least one injection of UST or VDZ during pregnancy or within the 2 months before conception and additional prospective evaluations regarding pregnancy outcomes with new biologics are needed.